[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematologic-malignancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematologic-malignancy":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,70,0,25,[9,48,85,114,133,159,186,213,235,259,280,323,343,373,398,420,441,475,496,525,544,563,589,614,632],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":47},"100593443","phase-2-a-study-of-belumosudil-in-people-at-risk-of-developing-graft-versus-host-disease-after-a-stem-cell-transplant-100593443",false,"NCT07006506","A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant","Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Patients ≥ 18 years-old at time of consent.\n* Diagnosis: hematologic malignancy in morphologic remission who will be treated with RI or NMA conditioning and GVHD prophylaxis CNI-based (CNI without PTCY) plus abatacept or PTCY-based (CNI with PTCY).\n* Recipients of 7-8\u002F8 related or unrelated HLA-matched or related haploidentical donor.\n* Peripheral blood stem cell graft\n* Allo-HCT day \\\u003C120 at time of consent\n\nPost-HCT inclusion criteria (within 3 weeks before start of belumosudil treatment)\n\n* Patient has received an allo-HCT transplant and is in morphologic remission (blasts \\\u003C5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed.\n* Patient has achieved engraftment. Engraftment is defined as ANC≥500\u002FμL and platelets ≥ 20000\u002FμL on 3 consecutive measurements (each occurring at least 1 day apart). The patient must not have had a platelet transfusion within 7 days before the first measurement.\n* Patient is ≥ 80 days and ≤ 20 days from allo-HCT infusion.\n* Karnofsky score ≥ 70%.\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN)\n* Total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia).\n* Glomerular filtration rate (GFR) ≥ 30 mL\u002Fmin\u002F1.73 m2\n* Female subjects of childbearing potential (≤ 50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months.\n\n  ° Sexually active females of childbearing potential enrolled in the study must agree to consistently use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes: \\* Intrauterine device (IUD) plus one barrier method \\* Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method \\* 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or \\* A vasectomized partner\n* For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* Recipient of CD34+ selected or engineered stem cell graft.\n* Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin).\n* Evidence of current uncontrolled cardiovascular conditions, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.\n* Pulmonary dysfunction with DLCO \\\u003C50% corrected for hemoglobin\n* Patients with an active secondary malignancy or prior malignancy requiring systemic therapy within the past 5 years. Exceptions include adequately treated localized non melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma), as well as localized prostate cancer considered low risk and stable under treatment or surveillance.\n\nPost-HCT exclusion criteria\n\n* Uncontrolled infection, including active hepatitis B and C. Definitive therapy for infection is required and must have no signs of progression within 7 days of the first day of study drug treatment.\n* Use of investigational agent within 14 days pre-HCT or anytime thereafter.\n* Active acute or chronic GVHD requiring systemic therapy (topical or local therapies are allowed).\n* Active treatment with corticosteroids at a dose of ≥ 0.25 mg\u002Fkg\u002Fday for non-GVHD indication.\n* Uncontrolled psychosis, active suicidal ideation, or psychiatric hospitalization within the past year\n* Female patient who is pregnant or breastfeeding.\n* Prior therapy with belumosudil.\n* Known allergy or sensitivity to belumosudil or any other ROCK2 inhibitor.","ALL","18 Years",{"count":20,"type":21},46,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.",[27,28,29],"Graft Versus Host Disease","Graft Vs Host Disease","Hematologic Malignancy",[27,28,29,31,32,33,34,35],"Hematologic malignancy in morphologic remission","Belumosudil","Stem Cell Transplant","Memorial Sloan Kettering Cancer Center","25-033","RECRUITING","2026-06-25",{"date":39,"type":40},"2026-06-29","ACTUAL",{"date":42,"type":40},"2025-05-21",{"date":44,"type":21},"2029-05-21",{"name":34,"class":46},"OTHER",8,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100616063","comparing-diosmin-hesperidin-and-loratadine-to-prevent-bone-pain-from-g-csf-in-patients-with-blood-cancers-100616063","NCT07300735","Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies","Inclusion Criteria:\n\n* Adults 18 to 65 years old\n* Receiving a G-CSF for one of the following indications:\n\nTreatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant\n\n* Patients with or without bone pain associated with G-CSF administration.\n* Willingness to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with solid tumors.\n* Pregnant or breastfeeding women.\n* Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.\n* Patients with pre-existing bone disorders or receiving bone modifying agents\n* Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.\n* Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim\n* Patients who are unable to understand or provide informed consent","65 Years",{"count":57,"type":21},88,[59],"NA","This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.\n\nThe study is comparing two oral medications for their effectiveness as a preventive treatment:\n\n* Diosmin-Hesperidin (a flavonoid supplement).\n* Loratadine (a common anti-allergy medication).\n\nThe core question the study is trying to answer is:\n\n* Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine?\n* Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?",[29,62,63],"Neutropenia","Bone Pain",[65,66,67,68,69,70,71,72,73,74],"Loratadine","Diosmin","Filgrastim","Granulocyte Colony Stimulating Factor","G-CSF Induced Bone Pain","Hesperidin","Flavonoid","Antihistamine","Prophylaxis","Randomized Controlled Trial","2026-06-23",{"date":77,"type":40},"2026-06-24",{"date":79,"type":40},"2025-03-01",{"date":81,"type":21},"2027-07",{"name":83,"class":46},"Alexandria University",1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":84},"100644736","phase-1-cd45ra-depleted-dli-for-the-prevention-of-viral-infections-in-high-risk-patients-after-haploidentical-transplantation-100644736","NCT07672964","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study","CD45RADLIPx","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Patients undergoing allogeneic hematopoietic stem cell transplantation (any conditioning regimen or graft source is allowed).\n* Presence of at least one high-risk factor for post-transplant viral infection (any of the following):\n* Age ≥50 years or ≤14 years\n* Non-sibling matched transplantation\n* In vivo or ex vivo T-cell depletion\n* Myeloablative conditioning\n* Conditioning containing radiotherapy\n* Second transplantation\n* CMV IgG or EBV IgG donor\u002Frecipient mismatch (donor positive, recipient negative)\n* History of grade II or higher acute graft-versus-host disease (aGVHD) after transplantation and use of high-dose corticosteroids (prednisone equivalent ≥1 mg\u002Fkg\u002Fday)\n* Availability of a suitable lymphocyte donor (see \"Donor Selection Criteria\").\n* Adequate organ function meeting the following laboratory criteria:\n* Liver function: ALT and AST ≤10× upper limit of normal (ULN); total bilirubin ≤5× ULN\n* Renal function: BUN and creatinine ≤1.25× ULN\n* No cardiac dysfunction on electrocardiogram or echocardiogram\n* Pulmonary function: oxygen saturation \\>90% without supplemental oxygen\n* The patient or legal guardian has the desire and request to receive treatment, signs the informed consent form before treatment, and is willing to comply with the treatment plan, follow-up schedule, and laboratory tests.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n* Active grade II-IV acute graft-versus-host disease (aGVHD)\n* Active aGVHD requiring prednisone or equivalent corticosteroid \\>0.5 mg\u002Fkg\u002Fday\n* Active viral infection\n* Uncontrolled or relapsed malignancy\n* Other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or affect informed consent, study participation, follow-up, or interpretation of results.","14 Years","50 Years",{"count":96,"type":21},30,[98],"PHASE1","The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\nDoes this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?",[29,101],"Haplo-identical HCT",[103,104],"CD45RA","DLI","NOT_YET_RECRUITING","2026-06-22",{"date":39,"type":40},{"date":109,"type":21},"2026-07-01",{"date":111,"type":21},"2028-07-31",{"name":113,"class":46},"Ruijin Hospital",{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":84},"100644312","phase-1-cd45ra-depleted-dli-for-the-treatment-of-refractorypersistent-viral-infections-after-haploidentical-transplantation-100644312","NCT07662369","CD45RA-depleted DLI for the Treatment of Refractory\u002FPersistent Viral Infections After Haploidentical Transplantation","Ex Vivo CD45RA-depleted DLI for the Treatment of Refractory\u002FPersistent Viral Infections After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study","CD45RADLITx","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Patients who have undergone hematopoietic stem cell transplantation.\n* Presence of viremia and\u002For viral infection-related disease caused by a single virus or multiple viruses among the following: CMV, EBV, ADV, BK, B19, JC, HHV-6B, HSV1, or HSV2.\n* Patients who, after ≥2 weeks of first-line therapy, have persistent viral positivity, no relief or worsening of clinical symptoms, or re-infection with the same pathogen after viral clearance.\n* Availability of a suitable lymphocyte donor.\n* Adequate organ function, meeting the following laboratory criteria:\n* Liver function: ALT and AST ≤ 10 × upper limit of normal (ULN), TBIL ≤ 5 × ULN.\n* Renal function: BUN and Cr ≤ 1.25 × ULN.\n* No cardiac insufficiency on electrocardiogram (ECG) or echocardiogram.\n* Pulmonary function: oxygen saturation \\> 90% on room air.\n* Willingness and ability of the patient or their legal guardian to receive treatment, comply with the treatment plan, follow-up schedule, and laboratory examinations, and provision of signed informed consent before any study-specific procedure.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n* Active grade II-IV acute graft-versus-host disease (aGVHD).\n* Prednisone or equivalent corticosteroid dose \\> 0.5 mg\u002Fkg\u002Fday.\n* Receipt of anti-thymocyte globulin (ATG), alemtuzumab (Campath), or other T-cell immunosuppressive monoclonal antibodies within 28 days before enrollment.\n* Less than 28 days after allogeneic transplantation, or receipt of donor lymphocyte infusion (DLI) or virus-specific T cell (VST) therapy within 28 days before enrollment.\n* Uncontrolled or relapsed malignancy.\n* Presence of other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or that may interfere with informed consent, study participation, follow-up, or interpretation of study results.",{"count":96,"type":21},[98,24],"The goal of this clinical trial is to learn whether giving patients special donor immune cells (called \"CD45RA Depleted DLI\") can help treat viral infections that have not improved with standard antiviral drugs. These infections occur after a stem cell transplant. The study will also look at the safety of this treatment.",[29,101],[103,104],{"date":75,"type":40},{"date":129,"type":21},"2026-06-01",{"date":131,"type":21},"2028-06-30",{"name":113,"class":46},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":84},"100219481","prospective-cohort-with-hemopathy-in-languedoc-roussillon-100219481","NCT02134574","Prospective Cohort With Hemopathy in Languedoc-Roussillon","Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon","HemoDiag","Inclusion criteria:\n\n* Age over 18\n* Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent\n* Having signed an informed consent\n* Affiliated with a social security scheme\n\nExclusion criteria:\n\n* Minor or major protected\n* Patients who have received treatment for hematological pathology",{"count":142,"type":21},500,"OBSERVATIONAL","Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.",[29],[147,148,149,150],"Lymphoma,","leukemia,","multiple myeloma,","hodgkin disease","2026-06-17",{"date":106,"type":40},{"date":154,"type":4},"2014-02",{"date":156,"type":21},"2033-06",{"name":158,"class":46},"University Hospital, Montpellier",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100560616","prospective-evaluation-of-delayed-effects-of-pediatric-car-t-cell-therapy-100560616","NCT06579469","Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy","Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)","Inclusion Criteria:\n\n* Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+\u002F- 14 days).\n\n  * Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.\n* Age ≤ 30 years at CAR T cell infusion.\n\nExclusion Criteria:\n\n* Active malignancy other than the disease under study.\n* Planned consolidative HSCT within 3 months post CAR T cell infusion.\n* Received or planned additional disease directed therapy post CAR T cell infusion.\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.","30 Years",{"count":168,"type":21},100,"This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and\u002For have damage to the nervous system.",[171,29,172],"B-ALL","Solid Tumor",[174,175],"CAR T cell infusion","Late Effects","2026-06-16",{"date":178,"type":40},"2026-06-18",{"date":180,"type":40},"2026-01-20",{"date":182,"type":21},"2029-03",{"name":184,"class":46},"St. Jude Children's Research Hospital",6,{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":84},"100603173","phase-4-allergy-delabeling-in-antibiotic-stewardship---intervention-100603173","NCT07133074","Allergy Delabeling in Antibiotic Stewardship - Intervention","Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention","RENEW-IN","Inclusion Criteria:\n\n* all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service\n* reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and\u002For carbapenem)\n\nExclusion Criteria:\n\n* patients with a history of severe cutaneous adverse reaction\n* patients with a history of Stevens-Johnson syndrome\n* patients with a history of toxic epidermal necrolysis\n* patients with a history of drug-induced exfoliative dermatitis\n* patients with a history of drug reaction with eosinophilia and systemic symptoms\n* patients with a history of acute generalized exanthematous pustulosis",{"count":195,"type":21},3800,[197],"PHASE4","The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.",[200,29],"Beta Lactam Allergy",[202,203,204],"penicillin allergy","hematologic cancer","allergy delabeling","2026-06-15",{"date":151,"type":40},{"date":208,"type":40},"2026-04-20",{"date":210,"type":21},"2029-11",{"name":212,"class":46},"Abramson Cancer Center at Penn Medicine",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":219,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":84},"100468784","response-to-influenza-vaccination-in-pediatric-oncology-patients-100468784","NCT05384288","Response to Influenza Vaccination in Pediatric Oncology Patients","Inclusion Criteria:\n\n* Patient ≤ 18 years old at the time of consent receiving care at St. Jude Children's Research Hospital\n* Diagnosed with a hematological malignancy\n* Eligible to receive the current seasonal influenza vaccine\n\nExclusion Criteria:\n\n• Previously received at least one dose of the current seasonal influenza vaccine.",{"count":220,"type":21},150,"Influenza infection occurring during oncologic treatment or following hematopoietic cell transplantation (HCT) is associated with increased risk of morbidity in the form of lower respiratory tract infection (LRTI) and mortality relative to otherwise healthy patients. The study participants have been diagnosed with a hematological malignancy and are eligible to receive the current seasonal influenza (Flu) vaccine.\n\nPrimary Objective\n\n* To determine the feasibility of opening a longitudinal prospective study of IIV immunogenicity in pediatric leukemia patients.\n* To describe the immunogenicity, as measured by the development of cell- and\u002For antibody-mediated influenza specific responses 3 to 5 weeks following vaccination, in a cohort of pediatric leukemia patients.\n\nSecondary Objectives\n\n* To describe whether an immune response, as measured by development of cell- and\u002For antibody-mediated influenza specific responses, is detectable 1-2 weeks following vaccination in a cohort of pediatric leukemia patients.\n* To describe the durability of immunogenicity by measuring cell - and antibody- mediated influenza specific responses at 6 months and 1 year following vaccination in a cohort of pediatric leukemia patients.\n\nExploratory Objectives\n\n* To estimate the clinical effectiveness of influenza vaccine in this cohort by monitoring for the development of clinical diagnosis of influenza in the cohort of enrolled pediatric oncology patients.\n* To correlate results of immune cell frequency in blood, as measured by complete blood count with differential, with development of an immune response to IIV.",[29,223,224],"Pediatric Cancer","Transplant-Related Cancer",[226],"Influenza infection","2026-06-11",{"date":229,"type":40},"2026-06-12",{"date":231,"type":40},"2022-10-07",{"date":233,"type":21},"2029-12-01",{"name":184,"class":46},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":258},"100546929","phase-3-an-extension-study-for-patients-previously-enrolled-in-studies-with-pelabresib-100546929","NCT06401356","An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib","Inclusion Criteria:\n\n1. Eligibility for Ongoing Pelabresib Treatment\n\n   * Able to provide signed informed consent, agreeing to all protocol and ICF requirements.\n   * At least 18 years old and legally able to consent in the study's jurisdiction.\n   * Previously enrolled and currently receiving pelabresib in a parent study.\n   * Demonstrating clinical benefit from pelabresib, as judged by the investigator.\n   * Willing and able to follow all study visits, treatments, and procedures.\n   * Agree to avoid pregnancy or fathering children:\n\n     * Men: Must use highly effective contraception (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.\n     * Women of childbearing potential (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.\n     * Women not of childbearing potential (surgically sterile or postmenopausal ≥12 months without other cause) are eligible.\n\n   Note: Women with amenorrhea due to chemo\u002Fradiotherapy are considered WOCBP and must use contraception.\n2. Eligibility for Survival Follow-up\n\n   * Provide signed informed consent, agreeing to all protocol and ICF requirements.\n   * Are at least 18 years old and legally able to consent.\n   * Were previously enrolled in a pelabresib clinical study.\n   * Are willing and able to comply with follow-up procedures.\n\nExclusion Criteria:\n\n1. Eligibility for Ongoing Pelabresib Treatment\n\n   * Legally institutionalized or under judicial protection.\n   * Enrolled in another interventional clinical trial (excluding the parent study).\n   * History of hypersensitivity to pelabresib, its excipients, or similar drugs.\n   * Significant gastrointestinal issues (e.g., active IBD, unresolved nausea\u002Fvomiting\u002Fdiarrhea \\> Grade 1) that may affect drug absorption.\n   * Any medical condition deemed unsuitable by the investigator.\n   * Uncontrolled illness or condition that may compromise safety or protocol compliance.\n   * Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea\u002Fanagrelide allowed up to 24 hours prior.)\n   * Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.\n   * Used strong CYP3A4 inhibitors\u002Finducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.\n   * Female participants who are pregnant, breastfeeding, or not using required contraception.\n   * Male participants who do not agree to use contraception or refrain from sperm donation as specified.\n   * Unwilling or unable to comply with the study protocol.\n2. Eligibility for Survival Follow-up • They are legally institutionalized or under judicial protection.",{"count":243,"type":21},50,[245],"PHASE3","The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and\u002For solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).",[29,172,248],"Advanced Malignancies","2026-06-10",{"date":227,"type":40},{"date":252,"type":40},"2024-08-13",{"date":254,"type":21},"2027-06-30",{"name":256,"class":257},"Novartis Pharmaceuticals","INDUSTRY",15,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":276,"leadSponsor":278,"locationsCount":84},"100636813","phase-1-clinical-study-of-the-safety-and-efficacy-of-allogeneic-tcr-enhanced-v2-t-cell-in-patients-with-malignant-tumors-100636813","NCT07570563","Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.","A Clinical Study on the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell Injection in the Treatment of Patients With Malignant Tumors","Inclusion Criteria:\n\n* Age 18-75 (inclusive).\n* Expected survival time ≥ 3 months.\n* Meets current clinical diagnostic criteria with a confirmed diagnosis of a malignant hematologic tumor or solid tumor, and has failed standard therapy (for solid tumors, at least one evaluable lesion according to RECIST v1.1 is required).\n* Adequate bone marrow reserve and essentially normal liver and kidney function (laboratory tests must meet the following criteria prior to the first allogeneic TCR-enhanced Vδ2 T cell treatment):\n* Hematology: White Blood Cell Count (WBC) ≥ 2.5×10⁹\u002FL, Lymphocyte Count (LY) ≥ 0.8×10⁹\u002FL, Hemoglobin (Hb) ≥ 80 g\u002FL, Platelets (PLT) ≥ 75×10⁹\u002FL.\n* Liver: ALT ≤ 3 × ULN; AST ≤ 3 × ULN; Total Bilirubin ≤ 3.0 × ULN.\n* Kidney: Serum Creatinine ≤ 1.5 × ULN.\n* Cardiac: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by echocardiogram.\n* Pulmonary: Normal oxygen saturation without supplemental oxygen.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1.\n* A negative pregnancy test is required for women of childbearing potential. Both male and female subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.\n* Able to understand the trial requirements and is willing to participate in the clinical study as required.\n* Voluntarily signs the informed consent form for the clinical trial.\n\nExclusion Criteria:\n\n* Known history of allergy, hypersensitivity, intolerance, or contraindication to allogeneic TCR-enhanced Vδ2 T cell or any components of the study drugs (including fludarabine, cyclophosphamide and albumin paclitaxel).\n* Continuous use of immunosuppressants within 1 month prior to allogeneic TCR-enhanced Vδ2 T cell infusion.\n* History of cerebrovascular accident or seizure within 6 months prior to signing the informed consent.\n* Symptomatic brain metastases.\n* Known psychiatric or substance abuse disorders that would compromise compliance with study requirements.\n* Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) with detectable Hepatitis B virus (HBV) DNA levels outside the normal reference range; positive for Hepatitis C virus (HCV) antibody with detectable HCV RNA; positive for Human Immunodeficiency Virus (HIV) antibody; positive for syphilis.\n* Severe cardiac disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA Class ≥ III), and severe arrhythmia.\n* Active or uncontrolled infection requiring systemic therapy (except for mild urogenital and upper respiratory tract infections).\n* Has not recovered from acute toxic effects of prior therapy (i.e., persisting hematological or organ toxicity ≥ Grade 2 related to prior therapy, excluding abnormalities associated with the study disease and its history).\n* Diagnosed with immunodeficiency.\n* Active infection requiring systemic treatment.\n* Female subjects of childbearing potential planning pregnancy within 2 years after cell infusion; or male subjects whose partners are planning pregnancy within 2 years after cell infusion.\n* Participation in another investigational drug clinical study within 1 month prior to screening.\n* Last anti-tumor therapy administered less than 5 half-lives of the drug prior to planned allogeneic TCR-enhanced Vδ2 T cell infusion.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation in this study.","75 Years",{"count":268,"type":21},24,[98,24],"The allogeneic TCR-enhanced Vδ2 T cell product is a novel genetically engineered cellular therapeutic. By engineering a specific BTN protein-binding moiety on its cell surface, this product harnesses the intrinsic tumoricidal potential of endogenous Vδ2 T cells and augments BTN protein recognition capability, thereby significantly boosting tumor cell killing potency. Notably, this engineered cell product exhibits no expression of co-stimulatory signaling domains and CD3ζ domains. This design circumvents T cell exhaustion triggered by overactivation and markedly enhances the in vivo persistence of therapeutic cells.\n\nThis is an open, prospective, open-label Phase I\u002FII clinical trial designed to assess the safety and therapeutic efficacy of allogeneic TCR-enhanced Vδ2 T cell injection in patients with relapsed or refractory hematologic malignancies and advanced solid tumors.",[29,172],"2026-06-05",{"date":274,"type":40},"2026-06-08",{"date":272,"type":40},{"date":277,"type":21},"2031-12-31",{"name":279,"class":46},"Chinese PLA General Hospital",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":290,"conditions":291,"keywords":309,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":322},"100526212","pharmacokinetic-study-of-venetoclax-tablets-crushed-and-dissolved-into-a-solution-100526212","NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution","A Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\n* Age: Patients must be \\\u003C39 years of age at time of study enrollment\n* Diagnosis: Patients may have a diagnosis of any hematologic malignancy\n* Central access: Patients must have an existing venous or arterial access line for PK blood draws\n* Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment\n* Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.\n* Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.\n* Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.","0 Years","38 Years",{"count":96,"type":21},"The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.\n\nPrimary Objectives\n\n• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution\n\nSecondary Objectives\n\n* To evaluate the safety of crushed venetoclax tablets administered as an oral solution\n* To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors\n* To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)\n* To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution",[29,292,293,294,17,295,296,297,298,299,300,301,302,303,304,305,306,307,308],"Leukemia","Lymphoma","Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","AML","Chronic Myelogenous Leukemia","CML","Myeloproliferative Neoplasm","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Burkitt Lymphoma","T-cell Lymphoma","B Cell Lymphoma","Peripheral T Cell Lymphoma","Cutaneous B-Cell Lymphoma",[310,311,312],"Venetoclax","Pediatric AML","Pediatric Relapsed\u002FRefractory AML","2026-06-02",{"date":315,"type":40},"2026-06-04",{"date":317,"type":40},"2023-11-15",{"date":319,"type":21},"2027-12-01",{"name":321,"class":46},"Children's Hospital Medical Center, Cincinnati",5,{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":329,"sex":17,"minAge":4,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":84},"100596968","phase-1-tcr-depleted-progenitor-cell-graft-with-early-memory-t-cell-dli-plus-selected-use-of-blinatumomab-in-nave-t-cell-depleted-haploidentical-donor-hematopoietic-cell-transplantation-for-hematologic-malignancies-100596968","NCT07052370","TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","Inclusion Criteria:\n\nRecipient:\n\n* Age less than or equal to 21 years\n* High risk hematologic malignancy whereas allogeneic transplantation is the current standard of care. This includes (but is not limited to):\n\n  * High risk ALL in CR1 or CR2,\n  * any ALL in CR3 or subsequent;\n  * AML in high risk CR1 (AML diagnosis includes myeloid sarcoma),\n  * any AML in CR2 or subsequent,\n  * any therapy related AML;\n  * MDS (primary or secondary),\n  * NK cell, biphenotypic, or undifferentiated leukemia\u002Flymphoma in CR1 or subsequent;\n  * CML in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor, or a history of blast crisis.\n* If prior CNS leukemia, it must be treated and in CNS CR\n* Left ventricular ejection fraction \\> 40%, or shortening fraction ≥ 25%\n* Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml\u002Fmin\u002F1.73m2\n* Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)\n* Bilirubin ≤ 3 times the upper limit of normal for age\n* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n\nDonor:\n\n* At least single haplotype matched (≥ 4 of 8) family member\n* At least 18 years of age\n* HIV negative\n* Regarding donation eligibility, is identified as either:\n\n  * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR\n  * Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271\n\nExclusion Criteria:\n\nRecipient:\n\n* Has a suitable HLA-identical sibling or suitable 12\u002F12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame.\n* Any other active malignancy other than the one for which this HCT is indicated\n* Received a prior allogeneic HCT at any time\n* Received an autologous HCT within the previous 6 months\n* Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment\n* Breast feeding\n* Any current uncontrolled bacterial, fungal or viral infection\n\nDonor:\n\n* Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female\n* If female, breast feeding",true,"21 Years",{"count":96,"type":21},[98],"This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI.\n\nThe primary objective is:\n\n\\- To assess the safety and feasibility of early CD45RA-depleted DLI administration.\n\nThe secondary objectives are\n\n* To assess the safety and feasibility of the addition of blinatumomab in the early post-transplant period in patients with CD19+ malignancy.\n* To measure and describe the pharmacokinetics of rabbit ATG in HCT recipients on this study.",[29],[336],"Hematopoietic Cell Transplant",{"date":313,"type":40},{"date":339,"type":40},"2025-09-25",{"date":341,"type":21},"2030-12",{"name":184,"class":46},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":350,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":360,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":84},"100569096","lets-get-real-family-health-communication-tool-in-pediatric-stem-cell-transplant-and-cellular-therapy-100569096","NCT06689800","Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Let's Get REAL: A Pilot Trial of a Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Inclusion Criteria Youth:\n\n* Children or adolescents 8-17 years of age referred for SCTCT.\n* Diagnosis of malignant or nonmalignant disorder.\n* Referred for any type of SCTCT. Autologous and allogeneic stem cell and cellular therapies are eligible.\n* Planning to meet with a provider to discuss SCTCT.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed assent document.\n* Must speak English and be cognitively able to participate.\n\nInclusion Criteria Parents:\n\n* Parent or guardian of a child 8-17 years of age with any diagnosis referred for any type of SCTCT. Diagnoses may include malignant and nonmalignant disorders. Autologous and allogeneic stem cell and cellular therapies are eligible. Parent or guardian is defined as an adult who usually cares for the youth and has authority to make medical decisions for them.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed consent document.\n* Must speak English and be cognitively able to participate.\n\nExclusion Criteria Youth:\n\n* Active medical problems severe enough to preclude study participation at the time of recruitment.\n\n  * Patients who are otherwise eligible, but whose primary transplant physician does not want them to participate in the study.\n* Lacks cognitive capacity to complete study activities, as determined by consenting professional.\n\nExclusion Criteria Parents:\n\n* Their youth referred for SCTCT does not assent to participate.","8 Years",{"count":352,"type":21},60,[59],"The investigators will conduct a pilot feasibility and efficacy trial of a newly developed family health communication tool (called Let's Get REAL) in increasing youth involvement in real-time stem cell transplant and cellular therapy decisions (SCTCT). The investigators will pilot the intervention among 24 youth and their parents, stratified by youth age (stratum 1, 8-12 years of age and stratum 2, 13-17 years of age).",[29,172,356,357,358,359],"Sickle Cell Disease","Aplastic Anemia","Immune Deficiency","Metabolic Disorder",[361,362,363,364,365],"Pediatric","Family","Decision making","Health Communication","Intervention",{"date":315,"type":40},{"date":368,"type":40},"2024-11-26",{"date":370,"type":21},"2026-11-30",{"name":372,"class":46},"Washington University School of Medicine",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":329,"sex":17,"minAge":18,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":381,"conditions":382,"keywords":383,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":84},"100581893","natural-history-study-to-determine-drug-metabolism-phenotype-and-appropriate-germline-source-dna-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplant-100581893","NCT06856226","Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant","* INCLUSION CRITERIA:\n* Age \\>=18 years\n* Participants must be enrolled on a clinical trial at the NIH Clinical Center (CC) under which they will donate or receive an allogeneic HSCT. The participant and their donor must enroll together to provide a complete set of samples for analysis.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Donors are not allowed to enroll without a recipient\n* Prior allogeneic HSCT\n* History of psychiatric disorder which may compromise compliance with protocol requirements.\n* Pregnant and lactating individuals","120 Years",{"count":57,"type":21},"Background:\n\nAfter an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.\n\nPost-HSCT recipients may receive a medication in which the dosing needs to be adjusted based on genetic variation.\n\nWhile genes in donor genome may influence dosing and administration of some agents, the majority of established gene-drug pairs in pharmacogenetics are related to expression of metabolic or transporting enzymes located in recipients tissues, often the liver.\n\nDetermining which genetic variants influence drug disposition in HSCT recipients is complicated by chimerism in samples that are routinely collected for determining genotype. However, chimerism in tissues is poorly studied in this patient population.\n\nObjectives:\n\nTo determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic HSCT.\n\nEligibility:\n\nPeople ages 18 years and older who are enrolled on a clinical trial at the NIH Clinical Center under which they will donate or receive an allogeneic HSCT.\n\nDesign:\n\nDNA is collected prior to HSCT and for two years after HSCT.\n\nBlood will be collected and skin fibroblast cell lines will be established prior to HSCT to serve as a reference genome.\n\nBlood, buccal cells, skin, and hair will be monitored for the development of mixed chimerism via detection of short tandem repeats. Liver biopsies will be collected from participants undergoing hepatic surgery.\n\nPharmacoscan arrays will be conducted to determine which samples are useful for pharmacogenetic testing in participants who receive allogeneic HSCT.\n\nA probe drug cocktail will be administered pre- and post-HSCT to determine if transplantation alters the metabolic phenotype of liver enzymes.\n\n...",[292,293,29],[384,336,385,386,387],"Allogeneic Transplant","Bone Marrow Transplant","peripheral blood transplant","Chimerism","2026-05-23",{"date":390,"type":40},"2026-05-27",{"date":392,"type":40},"2026-03-04",{"date":394,"type":21},"2028-12-01",{"name":396,"class":397},"National Cancer Institute (NCI)","NIH",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":419},"100640357","identifying-cellular-and-molecular-determinants-of-efficacy-and-resistance-in-patients-undergoing-car-t-therapy-100640357","NCT07609485","Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy","Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy at the CHU, Lille: Biological Prospective Collection and Storage","CAR-Lille","Inclusion Criteria:\n\n* Male or female aged ≥ 18 years and able to provide informed consent\n* Any indication,\n* Commercially available CART therapies,\n* Any conditioning.\n\nExclusion Criteria:\n\n* Freedom privacy\n* Absence of medical coverage\n* Patients receiving CART or CAR-based cellular therapies which are not commercially available.",{"count":407,"type":21},700,"In recent years we have witnessed a breakthrough in the treatment of leukemia and lymphoma using autologous CAR-T cells that can induce durable remission in patients. Multiple approved CAR-T therapy trials, including those at our centre, have consistently yielded objective tumor regression rates in about 40% of patients that have progressed after multiple previous chemo or targeted therapies. However, not all the patients respond to the therapy and rate of relapse is unfortunately common. Hence, the identification of biomarkers to track clinical activity of CAR-T and as predictive tools for patient selection is critical in our quest to develop personalized cellular therapies, where both degree and duration of response varies among different patients. For CAR-T therapy to truly live up to its promise, it is imperative to increase durable response rates. The success of CAR-T therapy not only depends in targeting antigens (e.x. CD19, BCMA) commonly expressed by malignant cells but also limited by poor persistence and trafficking of infused CAR-T cells in vivo. Hence highlighting the need to identify factors that exhibit optimal homing to the target sites and are able to persist long-term for continuous tumor surveillance. Furthermore, we lack comprehensive knowledge on how certain patients with leukemia and lymphoma achieve complete durable anti-cancer response upon CAR-T infusion whereas other either partially respond to the therapy and then relapse, or do not respond at all. Determining cellular and molecular factors that contribute to optimal homing of CAR-T cell to target sites as well as their long-term persistence will help us to design improved CAR-T based therapy against lymphoma other malignancies.",[410,29],"Cancer","2026-05-19",{"date":390,"type":40},{"date":414,"type":40},"2021-02-18",{"date":416,"type":21},"2028-02-18",{"name":418,"class":46},"University Hospital, Lille",2,{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":330,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":432,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":84},"100612733","phase-1-cd45ra-depleted-cd19-car-t-cell-consolidation-after-tcrcd19-b-cell-depleted-haploidentical-hematopoietic-cell-transplantation-for-relapsedrefractory-cd19-all-and-lymphoma-100612733","NCT07257419","CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+\u002FCD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed\u002FRefractory CD19+ ALL and Lymphoma","Inclusion Criteria:\n\nRecipient\n\n* Age less than or equal to 21 years\n* High risk hematologic malignancy where allogeneic transplantation is the current standard of care. This includes (but is not limited to):\n\n  * High risk CD19+ B cell ALL in CR1 or CR2\n  * Any CD19+ B-cell ALL in CR3 or subsequent\n* If prior CNS leukemia, it must be treated and in CNS CR\n* Left ventricular ejection fraction \\> 40%, or shortening fraction ≥ 25%\n* Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml\u002Fmin\u002F1.73m2\n* Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)\n* Bilirubin ≤ 3 times the upper limit of normal for age\n* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n\nDonor\n\n* At least single haplotype matched (≥ 4 of 8) family member\n* At least 18 years of age\n* HIV negative\n* If sexually active, agreement to use birth control until 2 weeks after completion of the mobilization and apheresis procedure\n* Regarding donation eligibility, is identified as either:\n\n  * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR\n  * Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271\n\nExclusion Criteria:\n\nRecipient\n\n* Has a suitable HLA-identical sibling or suitable 12\u002F12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame\n* Any other active malignancy other than the one for which this HCT is indicated\n* Received a prior allogeneic HCT at any time\n* Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment\n* If sexually active, agreement to use birth control until 6 months after T cell infusion\n* Breast feeding\n* Any severe current uncontrolled bacterial, fungal or viral infection\n\nDonor\n\n* Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female\n* If female, breast feeding",{"count":5,"type":21},[98],"The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.\n\nPrimary Objective:\n\n\\- To assess the safety and feasibility of combining CD19-CAR(Mem) T cells after TCRαβ+\u002FCD19 depleted haploidentical donor transplantation for pediatric patients with relapsed\u002Frefractory CD19+ B-cell malignancies.\n\nSecondary Objectives:\n\n* To estimate 1-year post-transplant overall survival, event-free survival, and GVHD-free relapse-free survival (GRFS).\n* To estimate cumulative incidence of engraftment, acute and chronic GVHD, and immune-related adverse events, including CRS and ICANS.",[430,431,29],"Relapsed Pediatric ALL","Hematopoietic Cell Transplantation",[433],"Relapsed\u002FRefractory ALL","2026-05-18",{"date":411,"type":40},{"date":437,"type":21},"2026-06-03",{"date":439,"type":21},"2035-12",{"name":184,"class":46},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":448,"targetDuration":450,"studyType":143,"phases":4,"briefSummary":451,"conditions":452,"keywords":457,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":84},"100485269","global-cardio-oncology-registry-100485269","NCT05598879","Global Cardio Oncology Registry","G-COR","Inclusion Criteria:\n\n* New cardio-oncology consultation for breast cancer patients, or\n* New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or\n* New cardio-oncology consultation for acute or chronic leukemia patients, or\n* New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or\n* New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.\n* All patients have to be 18 years old or older\n\nExclusion Criteria:\n\n* Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.\n* Minors less than 18 years old.\n* Inability or unwillingness to consent to participate",{"count":449,"type":21},5000,"24 Months","G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.",[453,29,454,455,456],"Breast Cancer","Immune Checkpoint Inhibitor-Related Myocarditis","Cardiotoxicity","Cardiovascular Diseases",[458,459,460,461,462,463,464,465],"cardiotoxicity","Cancer related cardiovascular diseases","prospective registry","international collaboration","social determinants of health","health care disparities","real world data","cardiology-oncology team work","2026-05-07",{"date":468,"type":40},"2026-05-12",{"date":470,"type":40},"2022-07-01",{"date":472,"type":21},"2029-07-01",{"name":474,"class":46},"The Cleveland Clinic",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":486,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":84},"100624773","expressive-writing-program-among-young-adults-with-blood-cancer-100624773","NCT07413991","Expressive Writing Program Among Young Adults With Blood Cancer","An Expressive Writing Program to Support Emotional Wellness Among Young Adults With Hematologic Malignancy","Inclusion Criteria:\n\n* Patient with a hematologic malignancy diagnosis in treatment or after treatment is completed, who is currently between the ages of 18 and 39 (young adult), or the informal caregiver of a young adult blood cancer patient\n* Located within the U.S., Canada, or U.S. territories\n* Able to read and write in English\n\nExclusion Criteria:\n\n* Located outside of the U.S., Canada, or its territories\n* Participant is a minor aged 17 years or below",{"count":168,"type":21},[59],"The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness.\n\nParticipants will\n\n* Take part in an online expressive writing workshop for four weeks\n* Take three surveys at different times over 12 weeks Researchers will compare changes in mental wellness reported by the participants of the workshop to those who will wait four weeks to start the workshop. After four weeks, the participants who are waiting will start their workshop.",[29],[487],"expressive writing","2026-05-01",{"date":466,"type":40},{"date":491,"type":40},"2026-02-01",{"date":493,"type":21},"2026-09-30",{"name":495,"class":46},"Blood Cancer United",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":503,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":506,"briefSummary":507,"conditions":508,"keywords":513,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":84},"100507421","phase-1-feasibility-and-safety-of-collecting-and-combining-autologous-hematopoietic-stem-cells-with-chimeric-antigen-receptor-car-t-cell-therapy-in-subjects-with-relapsedrefractory-hematological-malignancies-100507421","NCT05887167","Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed\u002FRefractory Hematological Malignancies","IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed\u002FRefractory Hematological Malignancies","Inclusion Criteria:\n\n* Age 18 - 85 years.\n* Histologically proven hematological malignancy according to the World Health Organization 2016 classification criteria for which a commercially available, FDA-approved CAR T product exists.\n* Relapsed or refractory disease, defined by the following:\n\n  * Disease progression after last regimen, or\n  * Refractory disease: failure to achieve a partial response (PR) or complete remission (CR) to the last regimen\n* At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy for the malignancy at the time the subject is planned for leukapheresis.\n* Toxicities due to prior therapy must be stable or recovered to ≤ Grade 1 with the exception of alopecia.\n* Subjects with an active uncontrolled infection should not start CAR T treatment until the infection has resolved.\n* Eastern cooperative oncology group (ECOG) performance status 0 - 2.\n* Adequate hematologic, hepatic, and cardiac function\n* Serum pregnancy test for women of childbearing potential (WOCBP) at Screening.\n* Willing to comply to research specimen collection as specified in the protocol.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Autologous hematopoietic cell transplant intent or execution within 8 weeks of planned CAR T infusion.\n* History of allogeneic cell transplantation within 8 weeks of planned CAR T infusion.\n* Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management at time of screening.\n* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment.\n* History of a seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, or any autoimmune disease with CNS involvement.\n* Doses of corticosteroids of greater than or equal to 5 mg\u002Fday of prednisone or equivalent doses of other corticosteroids and other immunosuppressive drugs are not allowed prior to enrollment. A washout period of 10 days prior to leukapheresis and 10 days prior to anti-CD19 CAR T cell administration is required.\n* Any medical condition likely to interfere with assessment of feasibility or safety of study treatment.\n* Live vaccine ≤ 6 weeks prior to planned start of conditioning regimen.\n* History of severe immediate hypersensitivity reaction to any of the agents used in this study.\n* Current pregnancy or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.\n* Subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after the completion of conditioning chemotherapy. Females who have undergone surgical sterilization or who have been postmenopausal for at least 1 year are not considered to be of childbearing potential.\n* In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.\n* Patients with obvious myeloid clonal hematopoiesis on the screening bone marrow biopsy will be excluded based on the risk of developing myeloid neoplasms with aHSC infusion.","85 Years",{"count":505,"type":21},20,[98],"The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed\u002Frefractory (r\u002Fr) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in the first 60 days post CAR T dosing, and also through the collection of adverse events (AEs) and serious adverse events (SAEs) as well as the durability of response after treatment with HSCs with CAR T. The study follows an open-label, single-center and single non-randomized cohort design. 20 subjects with r\u002Fr hematological malignancies will be enrolled and treated to evaluate the feasibility and preliminary safety of collecting autologous HSCs and combining them with CAR T-cell therapy.",[29,509,510,511,512,302],"Large B-cell Lymphoma","Acute Lymphoblastic Leukemia","Mantle Cell Lymphoma","Multiple Myeloma",[514,515,516,517],"CAR T-cell therapy","autologous hematopoietic stem cells","CAR T","CAR T therapy",{"date":466,"type":40},{"date":520,"type":40},"2024-03-02",{"date":522,"type":21},"2027-12-15",{"name":524,"class":46},"Joshua Sasine, MD, PhD",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":84},"100479906","phase-2-phase-ii-study-of-pirtobrutinib-with-venetoclax-in-relapsed-refractory-mcl-mantle-cell-lymphoma-patients-100479906","NCT05529069","Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","Inclusion Criteria:\n\n1. Confirmed diagnosis of mantle cell lymphoma in tissue biopsy by hematopathology with\u002Fwithout chromosome translocation t(11;14), (q13;q32) and\u002For overexpress cyclin D1 in tissue biopsy. Cyclin D1 negative MCL (confirmed by hematopathology at MDACC are allowed).\n2. The patient is able to take oral medications\n3. Relapsed MCL (irrespective of prognostic factors) including any lines or prior therapy or patients who had prior ibrutinib, acalabrutinib, zanubrutinib, other BTK inhibitor or anti CD19-CART therapy, single agent or in combination (without prior venetoclax) or relapsed high risk MCL including any or all of the following (Blastoid\u002Fpleomorphic histology), High Ki-67 (≥50%), TP53 mutated or del17p by FISH, NSD2, NOTCH2, CDKN2A mutated or MYC positive by FISH or MYC, Bcl2 amplification, complex karyotype or high risk biologic MIPI score\n4. Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.\n5. Age from \\>=18 years at the time of signing the informed consent.\n6. Patients may have at least 1 site of radiographically assessable disease (i.e., lymph node longest diameter \\[LDi\\] \\>= 1.5 cm, not necessary for disease assessable by positron emission tomography \\[PET\\]\u002Fcomputerized tomography \\[CT\\], extra nodal site \\>= 1.0 cm in LDi. Patients with BM only or GI only relapse are allowed.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.\n8. Disease free of prior malignancies with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma \"in situ\" of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy \\> 3 years pertaining to prior malignancy. PI could use judgment in the best interest of patients.\n9. Patients must have relapsed or refractory MCL (irrespective of prior BTK inhibitor or anti CD19 CART exposure).\n10. Prothrombin time (or international normalized ratio) and partial thromboplastin time not to exceed 1.2 times the institutional upper limit of normal range (patients with an elevated prothrombin time and known lupus anticoagulant may be eligible for participation after consulting the IND sponsor).\n11. Adequate BM function independent of growth factor or PRBC or platelet transfusion support (within 14 days of Screening assessment and criteria must be met on C1D1 without transfusion\u002FG-CSF within 7 days of assessment, per local laboratory reference range at screening as follows:\n\n    1. platelet count \\>=50, 000\u002Fmm3;\n    2. absolute neutrophil count (ANC) \\>= 1000\u002Fmm3 unless cytopenia is clearly due to marrow involvement from MCL\n    3. total hemoglobin \\>= 8 g\u002FdL (without transfusion support within 2 weeks of screening); If any of the above-mentioned cytopenias (a-c) are present due to significant BM involvement, at least 30% BM involvement by MCL (requiring transfusion or granulocyte colony-stimulating factor \\[G-CSF\\] support) MCL patients may proceed with enrollment after discussion with the PI or Co-PI. Cytopenias may not be due to evidence of myelodysplastic syndrome (MDS) or hypoplastic BM.\n12. Adequate organ function as defined by the following laboratory values:\n\n    1. Creatinine clearance. \\>=30 mL\u002Fmin (by Cockcroft-Gault method, APPENDIX I),\n    2. Total bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN with documented liver involvement and\u002For Gilbert's Disease or controlled immune hemolysis or considered an effect of regular blood transfusions.\n    3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C3 x ULN, or \\\u003C 5 x upper limit of normal if hepatic metastases are present.\n13. Projected life expectancy of \\>12 weeks pertaining to lymphoma.\n14. Female patients must be surgically sterile, postmenopausal (for at least 1 year), or have confirmed negative results for a pregnancy test at screening, on a blood or urine sample obtained within 7 days prior to initiation of study treatment.\n15. Women of childbearing potential and men with female partners of childbearing potential must be willing to use an effective form of contraception for at least 6 months after the last dose of study treatment. Patient enrolled into the Pirtobrutinib+ venetoclax study should use an effective form of contraception for 6 months after the last dose of Pirtobrutinib in combination with venetoclax, whichever time period is longer. Recommended methods of highly effective birth control are:\n\n    * Hormonal contraception (birth control pills, patches, or rings)\n    * Intrauterine device (IUD)\n    * Birth control injections\n    * Double barrier methods (diaphragm with spermicidal gel or condoms with birth control foam)\n    * Sterilization of participant or partner (\"tubes tied\" or vasectomy) Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal \\[and 2 years of non-therapy-induced amenorrhea\\] or surgically sterile) to observe conventional and highly effective birth control methods with failure rates of \\\u003C 1% for the duration of treatment and for 6 months following the last dose of study treatment; this must include barrier methods such as condom or diaphragm with spermicidal gel. Women of reproductive potential are defined as following menarche and not postmenopausal (and 2 years of non-therapy-induced amenorrhea) or surgically sterile. For male subjects with a non-pregnant female partner of child-bearing potential and a woman of child-bearing potential one of the following highly effective birth control methods with a failure rate of less than 1% per year when used consistently and correctly are recommended: Combined estrogen and progestin containing hormonal contraception associated with inhibition of ovulation given orally, intravaginally, or trans dermally, progestin-only hormonal contraception associated with inhibition of ovulation given orally, by injection, or by implant, Intrauterine device (IUD) , Intrauterine hormone-releasing system (IUS), Bilateral tubal occlusion, Vasectomized partner, Sexual abstinence: considered a highly effective method only if defined as refraining from heterosexual intercourse during an entire period of risk associated with the study treatment. The reliability of sexual abstinence will be evaluated in relation to the duration of the study and to the usual lifestyle of the subject (CTFG 2014).\n\n    Birth control methods unacceptable for this clinical trial are:\n    1. Periodic abstinence (calendar, hypothermal, or post-ovulation methods)\n    2. Withdrawal (coitus interruptus)\n    3. Spermicide only\n    4. Lactational amenorrhea method • Sperm donation is prohibited during the duration of participation on this protocol and for 6 months after the last dose of any study drug.\n16. Patients are required to have the following washout periods prior to planned Cycle 1 Day 1 (C1D1).\n\n    * Targeted agents, investigational agents, therapeutic monoclonal antibodies or cytotoxic chemotherapy: 5 half-lives or 2 weeks, whichever is shorter\n    * Immunoconjugates antibody treatment within 10 weeks prior to enrollment.\n    * Broad field radiation (≥ 30% of the bone marrow or whole brain radiotherapy) must be completed 28 days prior to study enrollment\n    * Palliative limited field radiation must be completed 7 days prior to study enrollment. Note: In the case of known central nervous system (CNS) involvement by systemic lymphoma: Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible if a compelling clinical rationale is provided by the Investigator and with documented IND sponsor's approval.\n17. Prior treatment-related AEs must have recovered to Grade ≤ 1 with the exception of alopecia and Grade 2 peripheral neuropathy.\n\nExclusion Criteria:\n\n1. Known central nervous system (CNS) involvement by lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease (as shown by MRI brain and\u002For CSF or clinical exam by neurologists may be eligible if a compelling clinical rationale is provided to institutional IND sponsor contact.)\n2. History of bleeding diathesis\n3. History of stroke or intracranial hemorrhage within 6 months of C1D1\n4. Vaccination with live vaccine within 28 days prior to enrollment.\n5. Have a known hypersensitivity to any of the excipients of Pirtobrutinib or to the intended covalent BTK inhibitor if randomized to control arm.\n6. Patients who experienced a major bleeding event or grade ≥ 3 arrhythmia on prior treatment with a BTK inhibitor. NOTE: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome).\n7. Pregnant or lactating females.\n8. Known and uncontrolled HIV infection. Participants with HIV (known HIV 1\u002F2 antibodies positive) are allowed if all of the following conditions are met:\n\n   * CD4+ T-cell counts ≥350 cells\u002FμL;\n   * Participants with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections may be eligible, if they have not had an opportunistic infection within the past 12 months;\n   * If participant is on antiretroviral, evaluation of the specific agents must be performed in order to determine if participant is eligible (e.g., excluding patients taking strong CYP3A inhibitors such as ritonavir). If necessary, evaluate the feasibility of switching to an alternate effective ARV therapy (ART) regimen before study participation. Participants need to be on established ART for at least 4 weeks and have an HIV viral load less than 400 copies\u002FmL prior to enrollment.\n   * Screening for HIV infection is not required\n9. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below: Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are hepatitis B PCR positive will be excluded. Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded.\n10. Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and IND sponsor may pose a risk for patient participation. Screening for chronic conditions is not required.\n11. Pregnancy, lactation or plan to breastfeed during the study or within 6 months of the last dose of study treatment\n12. Significant cardiovascular disease defined as:\n\n    * unstable angina or acute coronary syndrome within the past 2 months prior to enrollment\n    * history of myocardial infarction within 3 months prior to enrollment or\n    * documented LVEF by any method of ≤ 40% in the 12 months prior to enrollment\n    * ≥ Grade 3 NYHA functional classification system of heart failure, uncontrolled or symptomatic arrhythmias\n13. Prolongation of the QT interval corrected for heart rate (QTcF) \\> 470 msec on at least 2\u002F3 consecutive electrocardiograms (ECGs), and mean QTcF \\> 470 msec on ECG, during Screening. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT\u002F(RR0.33).\n\n    * Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.\n    * Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker.\n14. Concomitant malignancies or previous malignancies with less than a 1-year disease-free interval at the time of signing consent. Subjects with adequately treated basal or squamous cell carcinoma of the skin, or adequately treated carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis. Patients with controlled, advanced prostate cancer (not on active chemotherapy) are permitted. Active second malignancy unless in remission with life expectancy \\> 2 years. Examples include:\n\n    * a. Adequately treated no melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease.\n    * b. Adequately treated cervical carcinoma in situ without current evidence of disease.\n    * c. Localized (e.g., lymph node negative) breast cancer treated with curative intent with no evidence of active disease present for more than 3 years and receiving adjuvant hormonal therapy.\n    * d. Localized prostate cancer undergoing active surveillance.\n15. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of venetoclax.\n16. With known allergies to xanthine oxidase inhibitors and\u002For rasburicase.\n17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and\u002For would make the patient inappropriate for enrollment into this study.\n18. No concomitant anticancer therapies, immunotherapies, cellular, or radiotherapy. No major surgery within 4 weeks prior to first dose of study treatment. Washout period for chemotherapy is 14 days. Washout period for targeted agents is 2 weeks or 5 half-lives (t1\u002F2) (whichever is shorter). Washout period for antibody-based immunotherapies or cellular therapies is 4 weeks. Washout period for radiotherapy is 7 days (limited field) and 28 days (extended field that includes BM). Washout period must be completed prior to any treatment administration.\n19. Uncontrolled autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \\[AIHA\\], idiopathic thrombocytopenic purpura \\[ITP\\]) is for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.\n20. Concomitant steroids for disease related pain control are allowed at any dose but must be discontinued prior to any study treatment initiation. Chronic use of corticosteroids is allowed up to 20 mg prednisone or equivalent daily for non-cancer related conditions at the time of study start.\n21. History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T cell (CAR-T) therapy within 60 days of enrollment or presence of any of the following, regardless of prior SCT and\u002For CAR-T therapy timing: • active graft versus host disease (GVHD); • cytopenia from incomplete blood cell count recovery post-transplant; • need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity \\> Grade 1 from CAR-T therapy; • ongoing immunosuppressive therapy (\\> 20 mg prednisone or equivalent daily).\n22. Known neurologic disorder or residual neurologic toxicities that may put patients at increased risk of neurologic toxicity in the opinion of the investigator.\n23. Active uncontrolled systemic infection.\n24. Received an investigational agent within 2 weeks or within 5 T1\u002F2, whichever is shorter prior to the first dose of study treatment.\n25. Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and\u002For strong P-gp inhibitors. Because of their effect on CYP3A4, use of any of the following within 3 days of study therapy start or planned use during study participation is prohibited, • grapefruit or grapefruit products\n\n    * Seville oranges or products from Seville oranges\n    * star fruit\n26. Patients taking warfarin and\u002For equivalent vitamin K antagonists are excluded since the use of these agents is contraindicated with Pirtobrutinib or with venetoclax.",{"count":96,"type":21},[24],"To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).",[511,300,29],"2026-04-30",{"date":537,"type":40},"2026-05-05",{"date":539,"type":40},"2023-01-25",{"date":541,"type":21},"2027-04-28",{"name":543,"class":46},"M.D. Anderson Cancer Center",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":84},"100557027","mindfulness-intervention-for-sleep-disturbance-and-symptom-management-in-hematologic-cancer-patients-during-and-after-inpatient-treatment-100557027","NCT06532773","Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment","Inclusion Criteria:\n\n1. Male and female patients, \\>18 years old\n2. Initial or recurrent diagnosis of acute myeloid leukemia, acute lymphoblastic leukemia, Non-Hodgkin's lymphoma, multiple myeloma, or myelodysplastic syndrome\n3. at least 7 days of hospitalization for treatment (e.g., chemotherapy, CAR-T immunotherapy)\n4. 8 or greater on the Insomnia Severity Index with timeframe adjusted to be \"past 7 days\"\n5. Ability to speak and read English, and intact hearing and vision\n\nExclusion Criteria:\n\n1. Reported or suspected cognitive impairment, confirmed via Folstein Mini-Mental Status Exam \\\u003C25\n2. Serious psychiatric (e.g., schizophrenia, suicidal intent) or medical condition (e.g., seizure disorder, narcolepsy) indicated by medical chart, oncologist, or other provider\n3. Expected survival of \\\u003C6 months",{"count":352,"type":21},[59],"People with hematologic cancer often have sleep disturbance and symptoms of fatigue, stress, and pain. This study is being done to test a mindfulness intervention for sleep disturbance and symptom management in patients with hematologic cancer during and after inpatient treatment (Nite2Day+). Participants will complete a baseline survey online, using a mobile application, or paper\u002Fpencil. Once the baseline survey is complete, participants will be randomized (like a flip of a coin) to receive Nite2Day+ or Standard Care. Nite2Day+ will include activities during and after inpatient treatment. During inpatient treatment, participants will use a mobile app to access: 1) mindfulness meditations, 2) brief sleep education videos, and 3) brief videos teaching strategies to improve sleep quality in the hospital. After inpatient treatment, participants will complete 6, videoconference sessions (45-60 minutes) with a trained therapist to learn mindfulness and behavioral coping strategies to self-manage nighttime sleep disturbance and daytime symptoms of fatigue, stress, and pain. Three follow-up surveys will occur at hospital discharge, and approximately 8, and 12 weeks after hospital discharge. Participants randomized to Nite2Day+ will be given the option to complete an exit interview to provide feedback on the Nite2Day+ program. Participants randomized to Standard Care will only complete the four surveys. All participants will continue to receive their usual medical care. The total study duration is about 16 weeks.",[29],"2026-04-22",{"date":556,"type":40},"2026-04-23",{"date":558,"type":40},"2026-01-14",{"date":560,"type":21},"2029-06-30",{"name":562,"class":46},"Duke University",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":84},"100568102","feasibility-and-acceptability-of-primary-palliative-care-intervention-in-patients-undergoing-hematopoietic-stem-cell-transplantation-100568102","NCT06676852","Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation","Primary PC HCT","Inclusion Criteria:\n\n* Age 18 years or older\n* Undergoing autologous or allogeneic HCT at MGH\n\nExclusion Criteria:\n\n* Prior receipt of inpatient specialty palliative care on two prior admissions in the past 6 months.\n* Significant uncontrolled psychiatric disorders (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the primary oncologist believes prohibits informed consent or ability to participate in study procedures\n* Inability to comprehend English as this is a preliminary\u002Fpilot study",{"count":571,"type":21},40,[59],"Primary PC - or training HCT clinicians to deliver PC domains as part of routine practice - is an alternative model of supportive care. We have developed Sentinel, a primary PC intervention for HCT clinicians and patients. This study will assess Sentinel's feasibility and acceptability.",[336,29],[576,577,578,579],"palliative care","supportive care","primary palliative care","hematopoietic cell transplantation","2026-04-21",{"date":582,"type":40},"2026-04-24",{"date":584,"type":40},"2026-01-05",{"date":586,"type":21},"2027-03-30",{"name":588,"class":46},"Massachusetts General Hospital",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":22,"phases":599,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":84},"100488935","defining-the-role-of-palliative-care-for-patients-with-hematologic-malignancies-undergoing-adoptive-cellular-therapy-100488935","NCT05646576","Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy","Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study","PEACE","Inclusion Criteria:\n\n* Age 18 years or older.\n* Ability to complete surveys in English or with assistance of an interpreter.\n* Diagnosis of a hematologic malignancy.\n* Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.\n\nExclusion Criteria:\n\n* Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.\n* Already receiving palliative care (PC).",{"count":598,"type":21},90,[59],"The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.\n\nThe names of the study intervention groups involved in this study are:\n\n* Palliative care (PEACE) plus usual oncology care\n* Usual care (standard oncology care)\n\nParticipation in this research study is expected to last for up to 2 years.\n\nIt is expected that about 90 people will take part in this research study.",[29,602,293,292,512],"Blood Cancer",[29,604,605,293,292,512,606],"Adoptive Cellular Therapy","Palliative Care Intervention","Palliative Care","2026-04-16",{"date":580,"type":40},{"date":610,"type":40},"2022-12-30",{"date":612,"type":21},"2027-04-01",{"name":588,"class":46},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":84},"100471368","reduced-intensity-fludarabine-and-tbi-prior-to-haplo-identical-transplantation-100471368","NCT05417971","Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation","A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Availability of 3\u002F6 - 5\u002F6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells\n* KPS \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.\n\nExclusion Criteria:\n\n* Poor cardiac function (LVEF \\\u003C45%)\n* Poor pulmonary function (FEV, FVC, DLCO \\\u003C60%)\n* Poor liver function (bilirubin \\>\u002F= 2.5mg\u002FdL; AST or ALT \\>3xULN)\n* Poor renal function (creatinine clearance \\\u003C40mL\u002Fmin)\n* HIV-positive; active HepB or HepC\n* Uncontrolled infection\n* Pregnant female or not able to practice adequate contraception\n* Debilitating medical or psychiatric illness which would preclude their giving informed consent",{"count":505,"type":21},"This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.",[29],"2026-04-15",{"date":607,"type":40},{"date":627,"type":40},"2022-08-29",{"date":629,"type":21},"2026-12-31",{"name":631,"class":46},"Northside Hospital, Inc.",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":22,"phases":641,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":662},"100516228","phase-1-safety-and-tolerability-of-ziftomenib-combinations-in-patients-with-relapsedrefractory-acute-myeloid-leukemia-100516228","NCT06001788","Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed\u002FRefractory Acute Myeloid Leukemia","Key Inclusion Criteria:\n\n* Has been diagnosed with relapsed\u002Frefractory AML.\n* Has a documented NPM1 mutation or KMT2A rearrangement.\n* Has a documented FLT3 mutation (cA-3 only).\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2.\n* Has adequate hepatic and renal function as defined per protocol.\n* Has an ejection fraction above a protocol defined limit.\n* Participant, or legally authorized representative, must be able to understand and provide written informed consent prior to the first screening procedure.\n* Has agreed to use contraception as defined per protocol.\n\nKey Exclusion Criteria:\n\n* Has a diagnosis of acute promyelocytic leukemia or blast chronic myeloid leukemia.\n* Has clinically active central nervous system leukemia.\n* Has an active and uncontrolled infection.\n* Has a mean corrected QT interval (QTcF) \\> 480ms.\n* Has uncontrolled intercurrent illness, including, but not limited to protocol defined cardiac disease.\n* Has received radiation, chemotherapy, immunotherapy, or any other anticancer therapy including investigational therapy \\\u003C14 days or within 5 drug half-lives prior to the first dose of study intervention.\n* Has had major surgery within 4 weeks prior to the first dose of study intervention.\n* Has received a hematopoietic stem cell transplant (HSCT) and has not previously had adequate recovery per protocol defined criteria.\n* Has active graft-versus-host disease (GvHD) and or on immunosuppressive drugs for the treatment of GvHD\n* Participant is pregnant or lactating.",{"count":640,"type":21},171,[98],"The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed\u002Frefractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.",[296,644,29,645,646,647,292,648,649,650,651,652],"AML With Mutated NPM1","KMT2Ar","NPM1 Mutation","MLL Rearrangement","Acute Myeloid Leukemia","Leukemia, Myeloid","Leukemia, Myeloid, Acute","Acute Leukemia","Neoplasms by Histologic Type","2026-04-10",{"date":655,"type":40},"2026-04-14",{"date":657,"type":40},"2024-02-22",{"date":659,"type":21},"2027-08",{"name":661,"class":257},"Kura Oncology, Inc.",45]